Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.

Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS.

N Engl J Med. 2011 Aug 4;365(5):430-8. doi: 10.1056/NEJMoa1103975.

2.

Metabias: a challenge for comparative effectiveness research.

Goodman S, Dickersin K.

Ann Intern Med. 2011 Jul 5;155(1):61-2. doi: 10.7326/0003-4819-155-1-201107050-00010. No abstract available.

PMID:
21727295
3.

Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.

Scheinberg P, Marte M, Nunez O, Young NS.

Haematologica. 2010 Jul;95(7):1075-80. doi: 10.3324/haematol.2009.017889.

4.

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.

Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: Lancet Neurol. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea].

PMID:
20298967
5.

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience.

Quillen K, Wong E, Scheinberg P, Young NS, Walsh TJ, Wu CO, Leitman SF.

Haematologica. 2009 Dec;94(12):1661-8. doi: 10.3324/haematol.2009.010231.

6.

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.

Risitano AM, Selleri C, Serio B, Torelli GF, Kulagin A, Maury S, Halter J, Gupta V, Bacigalupo A, Sociè G, Tichelli A, Schrezenmeier H, Marsh J, Passweg J, Rotoli B; Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT).

Br J Haematol. 2010 Mar;148(5):791-6. doi: 10.1111/j.1365-2141.2009.08027.x. Epub 2009 Dec 7.

PMID:
19995389
7.

Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.

Piccinni C, Sacripanti C, Poluzzi E, Motola D, Magro L, Moretti U, Conforti A, Montanaro N.

Eur J Clin Pharmacol. 2010 Feb;66(2):199-206. doi: 10.1007/s00228-009-0739-z. Epub 2009 Oct 17.

PMID:
19838692
8.

Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia.

Gómez-Almaguer D, Jaime-Pérez JC, Garza-Rodríguez V, Chapa-Rodríguez A, Tarín-Arzaga L, Herrera-Garza JL, Ruiz-Argüelles GJ, López-Otero A, González-Llano O, Rodríguez-Romo L.

Ann Hematol. 2010 Mar;89(3):299-303. doi: 10.1007/s00277-009-0816-5. Epub 2009 Aug 25.

PMID:
19705116
9.

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL.

Blood. 2009 May 14;113(20):4834-40. doi: 10.1182/blood-2008-10-186999. Epub 2009 Mar 5.

10.

Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study.

Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM, Young NS.

Haematologica. 2009 Mar;94(3):348-54. doi: 10.3324/haematol.13829. Epub 2009 Jan 30.

11.

Why current publication practices may distort science.

Young NS, Ioannidis JP, Al-Ubaydli O.

PLoS Med. 2008 Oct 7;5(10):e201. doi: 10.1371/journal.pmed.0050201. No abstract available.

12.

A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome.

Kim H, Min YJ, Baek JH, Shin SJ, Lee EH, Noh EK, Kim MY, Park JH.

Leuk Res. 2009 Feb;33(2):222-31. doi: 10.1016/j.leukres.2008.08.004. Epub 2008 Sep 14.

PMID:
18790532
13.

Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy.

Moccia A, Ghielmini M.

Semin Hematol. 2008 Apr;45(2):75-84. doi: 10.1053/j.seminhematol.2008.02.006. Review.

PMID:
18381101
14.

Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.

Gómez-Almaguer D, Ruiz-Argüelles GJ, del Carmen Tarín-Arzaga L, González-Llano O, Gutiérrez-Aguirre H, Cantú-Rodríguez O, Jaime-Pérez J, Carrasco-Yalán A, Giralt S.

Biol Blood Marrow Transplant. 2008 Jan;14(1):10-5.

15.

Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.

Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, Cohen JI, Young NS, John Barrett A.

Blood. 2007 Apr 15;109(8):3219-24. Epub 2006 Dec 5.

16.

Current concepts in the pathophysiology and treatment of aplastic anemia.

Young NS, Calado RT, Scheinberg P.

Blood. 2006 Oct 15;108(8):2509-19. Epub 2006 Jun 15. Review.

17.

Alemtuzumab (Campath-1H): a systematic review in organ transplantation.

Morris PJ, Russell NK.

Transplantation. 2006 May 27;81(10):1361-7. Review.

PMID:
16732169
18.
19.
20.

Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab.

Kirk AD, Hale DA, Swanson SJ, Mannon RB.

Am J Transplant. 2006 May;6(5 Pt 1):1084-5. No abstract available.

Supplemental Content

Support Center